Your browser doesn't support javascript.
loading
The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia.
Wu, Xiaoxia; Lu, Shenqi; Zhang, Xinhui; Yang, Zhen; Sun, Aining; Wu, Depei; Zhou, Huifen; Miao, Miao.
Afiliación
  • Wu X; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China.
  • Lu S; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Zhang X; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China.
  • Yang Z; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Sun A; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China.
  • Wu D; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Zhou H; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China.
  • Miao M; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Cancer Med ; 13(17): e70161, 2024 Sep.
Article en En | MEDLINE | ID: mdl-39240182
ABSTRACT
Tyrosine kinase inhibitors (TKIs) have revolutionized Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treatment. The combination of blinatumomab and a TKI in the frontline setting has shown the safety and efficacy of the chemotherapy-free treatment approach in patients with Ph + ALL. This retrospective analysis included 19 patients with Ph + ALL and Ph-like ALL treated with the combination of blinatumomab and a TKI. Of the 14 newly diagnosed patients, the overall response, complete remission (CR), and molecular response (CMR) rates after one cycle of blinatumomab were 100% (10/10), 90% (9/10), and 57% (8/14), respectively. Of the five relapsed patients, the CR and CMR rates were 50% (2/4) and 40% (2/5). Blinatumomab in combination with TKIs is safe and effective and hence this combination therapy could be a viable therapeutic option in front-line treatment of patients with Ph + ALL.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cromosoma Filadelfia / Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Biespecíficos / Inhibidores de Proteínas Quinasas / Leucemia-Linfoma Linfoblástico de Células Precursoras Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Med Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cromosoma Filadelfia / Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Biespecíficos / Inhibidores de Proteínas Quinasas / Leucemia-Linfoma Linfoblástico de Células Precursoras Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Med Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos